New York, NY
Carlyle Hotel

View Map

Hosted by PwC’s Life Sciences & Deals Practice, join thought leaders and investors from across healthcare to discuss how data and technologies are changing the way medicines and devices are developed and brought to market, and how these innovations will impact deal flow and value creation in our industry. Inspiring keynotes. Panel debates. Collaborative workshops. Curated private meetings.

Our program opens with a networking breakfast and concludes with a formal dinner at Restaurant Daniel. The following agenda is designed for attendance of up to 50 participants. All events take place in the Carlyle Hotel’s Trianon and Versailles Suites, unless otherwise noted. Times are subject to change.

Why Attend DealsForum 2025

  • Network in an intimate setting with C-level executives, entrepreneurs and investors at the forefront of an evolving Pharmaceuticals and Life Sciences industry
  • Hear from thought leaders behind today’s most important industry deals and transactions
  • Debate with speakers and panelists about how big data, supercomputing and analytics are changing the way therapeutics are developed and delivered to the market
  • Attend private curated meetings to identify opportunities to accelerate your success
  • Dine with us at acclaimed Restaurant Daniel to close the day


This event is made possible through the assistance and support of PwC



Representatives of invited companies share strategically important lessons from a recent transaction. Mr. Schwartz will discuss the strategy evolution that helped deliver 23andMe’s recent data licensing agreement with Genentech. How might this deal formula inform your own company strategy?

Arivale CEO Clayton Lewis will offer a captivating vision of how the industry is changing, particularly as technology, patient data and consumerism become more important. He will discuss Arivale’ s innovative strategy to promote “scientific wellness,” which seeks to disrupt traditional and clinical pathways for treating chronic illnesses. Mr. Lewis is also a Partner at Maveron, the “consumer-only” venture firm based in Seattle. Q&A.

What curative value does a genetically tailored therapeutic have if the patient cannot stay on the protocol necessary to administer it? Jean-François Beaulé studies behavior science to help UnitedHealthcare assess and design innovative health plans that also support things like protocol compliance and healthy decision-making. He will discuss how he uses data, information and analytics to drive such assessments, leveraging what he calls “purposeful data” to empower “health ownership” among individuals. Includes Q&A.

How we measure success is changing; it is no longer a function of developing IP, clearing regulatory hurdles and generating revenue off an Rx. Today data is as valuable as a formulation. How is the power of consumer-generated data influencing how we evaluate strategic partnerships and the most valuable deals in the market? Given the growing importance of such data, among the technology giants, who will be the most desirable partners in executing the industry’s deals of the future?

Rowan Chapman, Managing Director, GE Ventures

Stephen Knight, M.D., President and Managing Partner, F-Prime Capital

Steve Schwartz, Vice President, Business Development & Strategy, 23andMe

Matthew Quinn, East Coast Managing Director, Healthcare and Life Sciences, Intel Corp.

MODERATOR: Carleen Hawn, Healthspottr CEO

This is a break for some, or the first of three curated 1-on-1 meeting sessions between fellow attendees and PwC hosts.

A leading industry CEO “in conversation” with PwC Partners. Moderated by Healthspottr’s Carleen Hawn. Includes Q&A.

Speakers share strategically important lessons from a recent transaction. Mr. Samuels shares insights from his decades-long career on Capitol Hill in helping companies navigate the legislative and regulatory maze of establishing novel payment and coverage mechanisms for their innovative therapeutics and devices.

Between the election cycle and health reform anew, Mr. Khosla shares his insights on the political and legislative developments — such as the tax extenders that are due to expire and the approaching debt ceiling — that could impact our industry in the coming year, and in particular, the way we invest in R&D. In conversation with Carleen Hawn. Joint Q&A with Dr. Jenkins to follow.

In her 20 years in biopharma, Dr. Jenkins has helped teams drive their innovations from scientific research through clinical development, regulatory approval and into the healthcare system globally. She will offer the entrepreneur’s perspective on the current trends influencing how we invest in R&D and bring our best ideas to market — including at Dimension, which celebrated its IPO on October 22. Joint Q&A with Jay Khosla.

This is the second of three curated 1-on-1 meeting sessions between fellow attendees and PwC hosts.

This is the third of three curated 1-on-1 meeting sessions between fellow attendees and PwC hosts.

PwC Principal Dimitri Drone and Healthspottr CEO Carleen Hawn


New collaborations pairing drug makers with insurers, health systems, patient groups and technology firms are reconfiguring drug R&D and commercialization. Shared data is shaping drug development and demonstrating health outcomes to create value for patients and industry.

21st Century Collaboration

Stay current and connected. Our timely publications, webcasts and news alerts will help you not only react, but anticipate and adapt, in today’s evolving business environment.

Subscription Management Link

As the health sector’s center of gravity shifts toward customers, savvy new players are moving fast to capitalize on the change. These new entrants are poised to shake up the industry, drawing billions of dollars in revenue from traditional healthcare organizations while building lucrative new markets in the burgeoning New Health Economy.

Healthcare New Entrants

A deal announced with Genentech points the way for 23andMe, the personal genetics company backed by Facebook billionaire Yuri Milner and Google Ventures to become a sustainable business – even if the company’s discussions with the U.S. Food and Drug Administration stretch on for years.

Surprise! With $60 Million Genentech Deal, 23andMe Has A Business Plan

Genetics. New manufacturing techniques. Demographic shifts. These are just a few of the forces changing the way industry players compete and collaborate. Are your analytics set up to help you quickly spot and evaluate new possibilities and impacts?

Global Data & Analytics Survey 2014

Q2 2015 saw a continued trend of deal activity with closed deal value of $72.2 billion from 46 transactions. Announced deals exceeded the prior quarter by 41% in value and 17% in volume.

The globalization of business models and dramatic changes in the way that businesses operate and compete have resulted in a shift in M&A strategy and execution. Joint ventures and strategic business alliances are an impactful way for companies to achieve their growth objectives to accompany organic growth and M&A.

Pharmaceutical and Life Sciences Deals Insights Quarterly Q2 2015

Confirmed Attendees

Lesley Bakker

PricewaterhouseCoopers LLP

Jean-Francois Beaule

Executive Vice President, Health Plan Design & Innovation, UnitedHealth Group

Meredith Berger

US Pharmaceutical & Life Sciences Industry Group, PricewaterhouseCoopers LLP

Sundeep Bhan

CEO, Medivo, Inc

Rowan Chapman

General Manager, GE

Ruoxi Chen

Vice President, Warburg Pincus

Ronald Chopoorian

Partner, PricewaterhouseCoopers LLP

Tom DeLay

COO, Healthspottr Media LLC

Dimitri Drone

Partner, Pharmaceutical and Life Sciences Leader, Transaction Services, PricewaterhouseCoopers LLP

Jeffrey Dunne

Principal, Deals Practice, PricewaterhouseCoopers LLP

Luke Harada

Vice President, Business Devlopment, C. R. Bard

Carleen Hawn

CEO & Co-Founder, Healthspottr Media LLC

Glenn Hunzinger

Partner, PricewaterhouseCoopers LLP

Annalisa Jenkins

CEO, Dimension Therapeutics

Jay Khosla

Policy Director, Senate Finance Committee

Sarah Kim

Principal, CD&R

Stephen Knight

Managing Partner, Fidelity Biosciences, F-Prime Capital

Craig Kocak

Partner, PricewaterhouseCoopers LLP

Geoff Levin

Partner, Sidley Austin LLP

Clayton Lewis

Partner, Arivale

Greg McGahan

Partner, Deals Practice, PricewaterhouseCoopers LLP

Andrew Miller

Partner, Transaction Services, PricewaterhouseCoopers LLP

Gabriel Otte

Chief Technology Officer & Co-Founder, Freenome

Sunil Patel

Head of Corp Development, Merck

Matthew Quinn

Managing Director for Health and Life Sciences, Intel Corp

Murray Ross, PhD

Vice President, Kaiser Foundation Health Plan; Executive Director, Institute for Health Policy, Kaiser Permanente

Marc Samuels, JD, MPH

Founder and CEO, ADVI

Steve Schwartz

Senior Vice President, Strategy & Corporate Development, Healthways

Shurjo Sen

Partner, Deals Practice, PricewaterhouseCoopers LLP

Gregory Simon

Executive Director, Cancer Task Force, White House Office of Science and Technology Policy

Laura Thrall

CEO, CureSearch

Jim Tunney

Partner, PricewaterhouseCoopers LLP

Roel Van den Akker

Director, Transaction Services, PricewaterhouseCoopers LLP

Karen Wilson

CEO, Blue Spot Health

Colin Wittmer

Partner, PricewaterhouseCoopers LLP

James Woods

Principal, PwC's Deals Practice, PricewaterhouseCoopers LLP